CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults

Trial Profile

CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Maraviroc (Primary) ; Maraviroc (Primary) ; Maraviroc (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms CHARM-03
  • Most Recent Events

    • 25 Aug 2016 Status changed to completed.
    • 30 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top